These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 22160378)

  • 1. KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice.
    Zhao L; Melenhorst JJ; Alemu L; Kirby M; Anderson S; Kench M; Hoogstraten-Miller S; Brinster L; Kamikubo Y; Gilliland DG; Liu PP
    Blood; 2012 Feb; 119(6):1511-21. PubMed ID: 22160378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gata2 deficiency delays leukemogenesis while contributing to aggressive leukemia phenotype in Cbfb-MYH11 knockin mice.
    Saida S; Zhen T; Kim E; Yu K; Lopez G; McReynolds LJ; Liu PP
    Leukemia; 2020 Mar; 34(3):759-770. PubMed ID: 31624376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.
    Growney JD; Clark JJ; Adelsperger J; Stone R; Fabbro D; Griffin JD; Gilliland DG
    Blood; 2005 Jul; 106(2):721-4. PubMed ID: 15790786
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Zhen T; Kwon EM; Zhao L; Hsu J; Hyde RK; Lu Y; Alemu L; Speck NA; Liu PP
    Blood; 2017 Nov; 130(22):2431-2442. PubMed ID: 29018080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice.
    Wang YY; Zhao LJ; Wu CF; Liu P; Shi L; Liang Y; Xiong SM; Mi JQ; Chen Z; Ren R; Chen SJ
    Proc Natl Acad Sci U S A; 2011 Feb; 108(6):2450-5. PubMed ID: 21262832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cbfb/Runx1 repression-independent blockage of differentiation and accumulation of Csf2rb-expressing cells by Cbfb-MYH11.
    Hyde RK; Kamikubo Y; Anderson S; Kirby M; Alemu L; Zhao L; Liu PP
    Blood; 2010 Feb; 115(7):1433-43. PubMed ID: 20007544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia.
    Nick HJ; Kim HG; Chang CW; Harris KW; Reddy V; Klug CA
    Blood; 2012 Feb; 119(6):1522-31. PubMed ID: 21937700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.
    Fischer J; Rossetti S; Datta A; Eng K; Beghini A; Sacchi N
    Mol Cancer; 2015 Jan; 14():7. PubMed ID: 25612891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.
    Schwind S; Edwards CG; Nicolet D; Mrózek K; Maharry K; Wu YZ; Paschka P; Eisfeld AK; Hoellerbauer P; Becker H; Metzeler KH; Curfman J; Kohlschmidt J; Prior TW; Kolitz JE; Blum W; Pettenati MJ; Dal Cin P; Carroll AJ; Caligiuri MA; Larson RA; Volinia S; Marcucci G; Bloomfield CD;
    Blood; 2013 Jan; 121(2):385-91. PubMed ID: 23160462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of CD200R1 in lineage-negative leukemic cells is characteristic of AML1-ETO-positive leukemia in mice.
    Kagiyama Y; Kitaura J; Togami K; Uchida T; Inoue D; Matsukawa T; Izawa K; Kawabata KC; Komeno Y; Oki T; Nakahara F; Sato K; Aburatani H; Kitamura T
    Int J Hematol; 2012 Nov; 96(5):638-48. PubMed ID: 23097187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia.
    Opatz S; Polzer H; Herold T; Konstandin NP; Ksienzyk B; Zellmeier E; Vosberg S; Graf A; Krebs S; Blum H; Hopfner KP; Kakadia PM; Schneider S; Dufour A; Braess J; Sauerland MC; Berdel WE; Büchner T; Woermann BJ; Hiddemann W; Spiekermann K; Bohlander SK; Greif PA
    Blood; 2013 Sep; 122(10):1761-9. PubMed ID: 23878140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RUNX1 and CBFβ-SMMHC transactivate target genes together in abnormal myeloid progenitors for leukemia development.
    Zhen T; Cao Y; Ren G; Zhao L; Hyde RK; Lopez G; Feng D; Alemu L; Zhao K; Liu PP
    Blood; 2020 Nov; 136(21):2373-2385. PubMed ID: 32929473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival.
    Schnittger S; Kohl TM; Haferlach T; Kern W; Hiddemann W; Spiekermann K; Schoch C
    Blood; 2006 Mar; 107(5):1791-9. PubMed ID: 16254134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic mastocytosis is uncommon in KIT D816V mutation positive core-binding factor acute myeloid leukemia.
    Kristensen T; Preiss B; Broesby-Olsen S; Vestergaard H; Friis L; Møller MB
    Leuk Lymphoma; 2012 Jul; 53(7):1338-44. PubMed ID: 22145956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic values of D816V KIT mutation and peri-transplant CBFB-MYH11 MRD monitoring on acute myeloid leukemia with CBFB-MYH11.
    Cho BS; Min GJ; Park SS; Park S; Jeon YW; Shin SH; Yahng SA; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ
    Bone Marrow Transplant; 2021 Nov; 56(11):2682-2689. PubMed ID: 34183780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. D816V mutation in the KIT gene activation loop has greater cell-proliferative and anti-apoptotic ability than N822K mutation in core-binding factor acute myeloid leukemia.
    Omori I; Yamaguchi H; Miyake K; Miyake N; Kitano T; Inokuchi K
    Exp Hematol; 2017 Aug; 52():56-64.e4. PubMed ID: 28506695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant.
    Chian R; Young S; Danilkovitch-Miagkova A; Rönnstrand L; Leonard E; Ferrao P; Ashman L; Linnekin D
    Blood; 2001 Sep; 98(5):1365-73. PubMed ID: 11520784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.
    Pan J; Quintás-Cardama A; Kantarjian HM; Akin C; Manshouri T; Lamb P; Cortes JE; Tefferi A; Giles FJ; Verstovsek S
    Blood; 2007 Jan; 109(1):315-22. PubMed ID: 16912224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation of microRNAs 222/221 in acute myelogenous leukemia with deranged core-binding factor subunits.
    Brioschi M; Fischer J; Cairoli R; Rossetti S; Pezzetti L; Nichelatti M; Turrini M; Corlazzoli F; Scarpati B; Morra E; Sacchi N; Beghini A
    Neoplasia; 2010 Nov; 12(11):866-76. PubMed ID: 21076613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Runx1 is required for hematopoietic defects and leukemogenesis in Cbfb-MYH11 knock-in mice.
    Hyde RK; Zhao L; Alemu L; Liu PP
    Leukemia; 2015 Aug; 29(8):1771-8. PubMed ID: 25742748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.